Humanistic burden of problem joints for children and adults with haemophilia
dc.contributor.author | Burke, Tom | |
dc.contributor.author | Rodriguez-Santana, Idaira | |
dc.contributor.author | Chowdary, Pratima | |
dc.contributor.author | Curtis, Randall | |
dc.contributor.author | Khair, Kate | |
dc.contributor.author | Laffan, Michael | |
dc.contributor.author | McLaughlin, Paul | |
dc.contributor.author | Noone, Declan | |
dc.contributor.author | O'Mahony, Brian | |
dc.contributor.author | Pasi, John | |
dc.contributor.author | Skinner, Mark W. | |
dc.contributor.author | O'Hara, Jamie | |
dc.date.accessioned | 2022-12-27T20:00:17Z | |
dc.date.available | 2022-12-27T20:00:17Z | |
dc.date.issued | 2022-12-27 | |
dc.identifier | https://chesterrep.openrepository.com/bitstream/handle/10034/627400/hae.14731.pdf?sequence=3 | |
dc.identifier.citation | Burke, T., Rodriguez‐Santana, I., Chowdary, P., Curtis, R., Khair, K., Laffan, M., McLaughlin, P., Noone, D., O'Mahony, B., Pasi, J., Skinner, M., & O'Hara, J. (2022). Humanistic burden of problem joints for children and adults with haemophilia. Haemophilia, 29(2), 608-618. https://doi.org/10.1111/hae.14731 | |
dc.identifier.issn | 1351-8216 | |
dc.identifier.doi | 10.1111/hae.14731 | |
dc.identifier.uri | http://hdl.handle.net/10034/627400 | |
dc.description.abstract | Introduction: The “problem joint” (PJ) concept was developed to address patient‐centric needs for a more holistic assessment of joint morbidity for people with haemophilia (PwH). Aim: To quantify the humanistic burden of PJs in PwH to further support validation of the PJ outcome measure. Methods: Multivariable regression models evaluated the relationship between PJs and health‐related quality of life (HRQoL, EQ‐5D‐5L) and overall work productivity loss (WPL) using data from the ‘Cost of HaEmophilia: a Socioeconomic Survey’ population studies (adults: CHESS II, CHESS US+; children/adolescents: CHESS‐Paeds). Covariates included were haemophilia severity, age, comorbidities and education. Results: The CHESS II sample included 292 and 134 PwH for HRQoL and WPL analyses, mean age 38.6 years (39% ≥1 PJ, 61% none). CHESS US+ included 345 and 239 PwH for HRQoL and WPL, mean age 35 years (43% ≥1 PJ, 57% none). CHESS‐Paeds included 198 PwH aged 4–17 (HRQoL only), mean age 11.5 years (19% ≥1 PJ, 81% none). In CHESS II and CHESS US+, presence of PJs was associated with worse HRQoL (Both p < .001). Few CHESS‐Paeds participants had PJs, with no significant correlation with HRQoL. In CHESS II, upper body PJs were significantly correlated to WPL (p < .05). In CHESS US+, having ≥1 PJ or upper and lower body PJs were significantly correlated to WPL (vs. none; both p < .05). Conclusion: This study has shown a meaningful burden of PJs on PwH, which should be considered in clinical and health policy assessments of joint health. | |
dc.language | en | |
dc.publisher | Wiley | |
dc.relation.url | https://onlinelibrary.wiley.com/doi/10.1111/hae.14731 | |
dc.rights | Licence for VoR version of this article: http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | issn: 1351-8216 | |
dc.source | issn: 1365-2516 | |
dc.subject | haemarthrosis | |
dc.subject | haemophilia | |
dc.subject | humanistic burden | |
dc.subject | problem joint | |
dc.subject | productivity impairment | |
dc.subject | quality of life | |
dc.title | Humanistic burden of problem joints for children and adults with haemophilia | |
dc.type | Article | |
dc.contributor.department | HCD Economics; The Innovation Centre; Royal Free London NHS Foundation Trust; Hematology Utilization Group Study (HUGS); Imperial College London; European Haemophilia Consortium; Irish Haemophilia Society; Barts and the London School of Medicine and Dentistry; McMaster University; Institute for Policy Advancement Ltd; University of Chester | |
dc.identifier.journal | Haemophilia | |
dc.date.updated | 2022-12-27T20:00:17Z | |
dc.description.funding | Funder: Sanofi, BioMarin, Takeda, Bayer, Roche, Swedish Orphan Biovitrum AB (Sobi), Novo Nordisk and SHIRE | |
dc.identifier.volume | 29 | |
dc.date.accepted | 2022-12-14 | |
dc.source.issue | 2 | |
dc.source.beginpage | 608-618 |